Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2033200431
JPRN-jRCT2033200431RecruitingPhase 1

A phase 1 clinical trial of intraperitoneal administration of GPC3-CAR expressing iPS cell-derived innate lymphoid/natural killer cells for patients with GPC3 positive advanced ovarian clear cell carcinoma with peritoneal dissemination

Harano Kenichi0 sites18 target enrollmentStarted: March 18, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
18
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
Female

Inclusion Criteria

  • •1. 1st time registration
  • •1) Histologically diagnosed advanced or metastatic ovarian clear cell carcinoma with radiographically confirmed peritoneal metastases irrespective of metastases in other organs.
  • •2) Patients who have progressed after receiving standard treatments for ovarian cancer.
  • •3) At least one measurable lesion as defined by RECIST ver.1.1, and/or non-target lesion such as the malignant ascites retention.
  • •4) Tumor must be glypican-3-positive by immunohistochemistry.
  • •5) Age at registration is of 20 years or older.
  • •6) ECOG Performance status, 0-2.
  • •7) HLA typing, HLA-A24 or HLA-B52.
  • •8) Adequate organ function by laboratory parameters within 7 days prior to the enrollment.
  • •9) A non-pregnant female. Female of childbearing potential who are negative in a pregnancy test within 7 days before enrollment. Patients should agree to use an adequate method of contraception in this study and in the future.
  • •10) The patient survival is expected to be longer than 3 months after registration.
  • •11) Patients who provided written informed consent to be subjects in this study.
  • •2. 2nd time registration
  • •1)-11) Patients met inclusion Criteria of 1st time registration.
  • •12) Patients who was able to produce iCAR-ILC-N101 at least 0.5 x 10^6 cells/kg/dose based on weight at the time of apheresis.

Exclusion Criteria

  • •1. 1st time registration
  • •1) Synchronous or metachronous (within 2 years) malignancies.
  • •2) Patients who has or is suspected to have bacterial infection or virus infection.
  • •3) Patients who require platelet or red blood cell transfusion within 14 days prior to the apheresis.
  • •4) Severe cardiovascular disease.
  • •5) Has concurrent interstitial lung disease/pneumonitis, or a history of (noninfectious) interstitial lung disease/pneumonitis that required treatment with steroids.
  • •6) History of hypersensitivity reactions to biological ingredients.
  • •7) Females who are pregnant or breastfeeding.
  • •8) History of the therapy derived from induced pluripotent stem cells.
  • •9) Has pericardial effusion, pleural effusion requiring any therapies.
  • •10) Has a history of cerebral infarction, cerebral hemorrhage, or transient cerebral ischemia within 180 days prior to enrollment.
  • •11) Has a history of deep vein thrombosis or pulmonary embolism.
  • •12) Is receiving systemic corticosteroids therapy or systemic immunosuppressive therapy.
  • •13) Has received a live vaccine within 28 days prior to enrollment.
  • •14) Has active brain metastasis or a tumor causing spinal cord compression.
  • •15) Patients who is considered to interfere with evaluation of the study therapy or safety or interpretation of study results.
  • •2. 2nd time registration
  • •1)-15) Patients met exclusion Criteria of 1st time registration.
  • •16) Has received prior antitumor therapy (e.g., chemotherapy, molecular-targeted therapy, therapeutic antibody, endocrine therapy, immunotherapy, and investigational therapy) or other investigational drug after 1st time registration.
  • •17) Has received radiotherapy after 1st time registration.
  • •18) Has received surgery under general anesthesia within 28 days prior to 2nd time registration.
  • •19) Is not eligible to enroll in the clinical trial based on the judgment by the Principal Investigator or Sub-investigator.

Investigators

Sponsor
Harano Kenichi

Similar Trials

Recruiting
Phase 1
Clinical trial of repeated intraperitoneal administration of GAIA-102 in patients with advanced gastrointestinal cancer (gastric cancer / pancreatic cancer) of microsatellite stable (MSS) with malignant ascites (Phase I / II Investigator-initiated clinical trial)Advanced gastrointestinal cancer of microsatellite stablegastric cancer, pancreatic cancerGastrointestinal Neoplasms
JPRN-jRCT2073220017Eiji Oki96
Completed
Phase 1
Phase I/II study of intravenous and intraperitoneal paclitaxel combined with continuous intraperitoneal cisplatin for advanced gastric cancer with peritoneal metastasisadvanced gastric cancer with peritoneal metastasis
JPRN-UMIN000002257Department of Surgical Oncology, The University of Tokyo25
Completed
Not Applicable
Phase I/II study of intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapyPeritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy
JPRN-UMIN000016670Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine35
Recruiting
Not Applicable
The study on the efficacy of intraperitoneal administration of triamcinolone acetonide to cancerous ascites in end-of-life patientscancer
JPRN-UMIN000034123Ashiya Municipal Hospital15
Not yet recruiting
Phase 1
Mesenchymal Stem Cell Therapy For Covid 19
CTRI/2020/08/027043eurogen Brain and Spine Institute